Tailoring treatment with targeted therapies for advanced colorectal cancer

1 Cunningham D Humblet Y Siena S Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Eng J Med 2004; 351:337–45.

2 Tejpar S Peeters M Humblet Y Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data. J Clin Oncol 2007; 25(18S):4037.

3 Tejpar S Peeters M Humblet Y Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): the EVEREST experience (preliminary data). J Clin Oncol 2008; 26(15S):4001.

4 Van Cutsem E Lang I D’haens G KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol 2008; 26(5S):2.

5 Bokemeyer C Bondarenko I status Hartmann JT. KRAS of efficacy first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 2008; 26(5S):4000.

6Di Nicolantonio F, Miriam M, Molinari F Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26:5705–12.